MAURO MICHELE P.
- Country
- Italy
- Department
- Clinical Dermatology
Research Overview
- Phase 3 Randomized Study of IO102-IO103 and Pembrolizumab Versus Pembrolizumab Monotherapy in Untreated Unresectable or Metastatic Melanoma
- Efficacy, Safety, and Tolerability of Pioglitazone with NB-UVB in Adult Patients with Active Non-Segmental Vitiligo: A Phase 2 Multi-Center Study
- “A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vitiligo”
Data & Insights
Has run more than one trial at 2 of 67 partner sites.
Specializations
Melanoma Research
This investigator specializes in advanced treatment approaches for unresectable and metastatic melanoma, with particular attention to innovative therapeutic combinations.
- Advanced Cutaneous Melanoma Treatment
- NRAS Mutant Melanoma Therapy
- Metastatic Disease Management
The research focus encompasses novel treatment strategies for both previously treated and untreated melanoma patients.
Immunotherapy Applications
The investigator explores immunotherapeutic approaches in melanoma treatment, particularly focusing on combination therapies with pembrolizumab.
- Immune Checkpoint Inhibition
- Combination Immunotherapy
- Treatment Response Assessment
Their work evaluates therapeutic efficacy through progression-free survival outcomes in advanced melanoma cases.
Targeted Therapies
The investigator studies targeted therapeutic approaches, specifically investigating molecular pathway inhibition in melanoma treatment.
- NRAS-Targeted Treatments
- Combination Drug Strategies
- Treatment Optimization
Research includes comparative analyses of various therapeutic options for treatment-resistant melanoma.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.